Avadel Pharmaceuticals (AVDL) Revenue & Revenue Breakdown
Avadel Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$27.96M
Latest Revenue (Q)
$41.50M
Main Segment (Y)
Vazculep
Main Geography (Y)
UNITED STATES
Avadel Pharmaceuticals Revenue by Period
Avadel Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $27.96M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $22.33M | -62.28% |
| 2019-12-31 | $59.22M | -42.66% |
| 2018-12-31 | $103.27M | -40.22% |
| 2017-12-31 | $172.74M | 14.97% |
| 2016-12-31 | $150.25M | -13.26% |
| 2015-12-31 | $173.21M | 1072.31% |
| 2014-12-31 | $14.78M | -34.17% |
| 2013-12-31 | $22.44M | -14.01% |
| 2012-12-31 | $26.10M | -19.94% |
| 2011-12-31 | $32.60M | -12.12% |
| 2010-12-31 | $37.09M | -11.93% |
| 2009-12-31 | $42.12M | 9.06% |
| 2008-12-31 | $38.62M | 5.36% |
| 2007-12-31 | $36.65M | 59.23% |
| 2006-12-31 | $23.02M | -2.45% |
| 2005-12-31 | $23.60M | -57.41% |
| 2004-12-31 | $55.41M | 120.17% |
| 2003-12-31 | $25.17M | 36.73% |
| 2002-12-31 | $18.41M | 40.64% |
| 2001-12-31 | $13.09M | 20.04% |
| 2000-12-31 | $10.90M | -1.25% |
| 1999-12-31 | $11.04M | 15.94% |
| 1998-12-31 | $9.52M | 17.56% |
| 1997-12-31 | $8.10M | 65.31% |
| 1996-12-31 | $4.90M | - |
Avadel Pharmaceuticals generated $27.96M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 27.08% compared to the same period a year ago.
Avadel Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $41.50M | 113.36% |
| 2023-12-31 | $19.45M | 177.35% |
| 2023-09-30 | $7.01M | 368.85% |
| 2023-06-30 | $1.50M | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2020-09-30 | $14.23M | 41.01% |
| 2020-06-30 | $10.09M | -17.58% |
| 2020-03-31 | $12.24M | 11.35% |
| 2019-12-31 | $10.99M | -22.73% |
| 2019-09-30 | $14.23M | -18.94% |
| 2019-06-30 | $17.55M | 6.80% |
| 2019-03-31 | $16.44M | -21.43% |
| 2018-12-31 | $20.92M | 5.52% |
| 2018-09-30 | $19.83M | -32.17% |
| 2018-06-30 | $29.23M | -12.20% |
| 2018-03-31 | $33.29M | -2.79% |
| 2017-12-31 | $34.25M | -13.68% |
| 2017-09-30 | $39.67M | -14.33% |
| 2017-06-30 | $46.31M | -11.80% |
| 2017-03-31 | $52.51M | 21.87% |
| 2016-12-31 | $43.09M | 34.28% |
| 2016-09-30 | $32.09M | -17.42% |
| 2016-06-30 | $38.86M | 7.30% |
| 2016-03-31 | $36.22M | -16.49% |
| 2015-12-31 | $43.37M | -8.35% |
| 2015-09-30 | $47.32M | -4.97% |
| 2015-06-30 | $49.80M | 52.16% |
| 2015-03-31 | $32.73M | -444.12% |
| 2014-12-31 | $-9.51M | -235.32% |
| 2014-09-30 | $7.03M | -13.04% |
| 2014-06-30 | $8.08M | -11.91% |
| 2014-03-31 | $9.18M | 48.49% |
| 2013-12-31 | $6.18M | 10.68% |
| 2013-09-30 | $5.58M | 0.76% |
| 2013-06-30 | $5.54M | 7.80% |
| 2013-03-31 | $5.14M | -29.69% |
| 2012-12-31 | $7.31M | 35.42% |
| 2012-09-30 | $5.40M | -10.53% |
| 2012-06-30 | $6.03M | -18.03% |
| 2012-03-31 | $7.36M | -14.90% |
| 2011-12-31 | $8.65M | -17.11% |
| 2011-09-30 | $10.43M | 54.51% |
| 2011-06-30 | $6.75M | -0.16% |
| 2011-03-31 | $6.76M | -49.71% |
| 2010-12-31 | $13.45M | 67.28% |
| 2010-09-30 | $8.04M | 7.00% |
| 2010-06-30 | $7.51M | -7.07% |
| 2010-03-31 | $8.09M | -23.64% |
| 2009-12-31 | $10.59M | 7.00% |
| 2009-09-30 | $9.90M | 3.37% |
| 2009-06-30 | $9.57M | -20.57% |
| 2009-03-31 | $12.05M | 27.34% |
| 2008-12-31 | $9.47M | 3.62% |
| 2008-09-30 | $9.13M | -0.20% |
| 2008-06-30 | $9.15M | -15.76% |
| 2008-03-31 | $10.87M | 2.88% |
| 2007-12-31 | $10.56M | - |
Avadel Pharmaceuticals generated $41.50M in revenue during Q2 2024, up 113.36% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Avadel Pharmaceuticals Revenue Breakdown
Avadel Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 |
|---|---|
| Vazculep | $10.43M |
| Other Products | $159.00K |
| Bloxiverz | $2.20M |
| License | - |
| Akovaz | $9.54M |
Avadel Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 20: Vazculep (46.70%), Akovaz (42.74%), Bloxiverz (9.85%), and Other Products (0.71%).
Quarterly Revenue by Product
| Product/Service | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|
| Vazculep | $4.92M | $5.51M | $8.79M | $9.41M | $9.47M | $8.76M | $11.38M | $12.96M |
| Other Products | $180.00K | $-21.00K | $-231.00K | $-160.00K | $604.00K | $373.00K | $31.00K | $1.83M |
| Bloxiverz | $800.00K | $1.40M | $1.47M | $2.36M | $2.57M | $3.66M | $5.54M | $7.49M |
| Akovaz | $4.20M | $5.35M | $4.21M | $5.95M | $3.79M | $5.99M | $11.88M | $10.22M |
| Product | - | - | $14.23M | $17.55M | $16.44M | $19.83M | - | - |
| License | - | - | - | - | - | - | - | - |
| Noctiva | - | - | - | - | - | $1.05M | $289.00K | $666.00K |
Avadel Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 20: Vazculep (48.71%), Akovaz (41.58%), Bloxiverz (7.93%), and Other Products (1.78%).
Avadel Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 |
|---|---|
| IRELAND | - |
| UNITED STATES | $22.33M |
Avadel Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: UNITED STATES (100.00%).
Avadel Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMRX | Amneal Pharmaceuticals | $2.39B | $701.78M |
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| ASRT | Assertio | $152.07M | $31.13M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| DERM | Journey Medical | $79.18M | $14.86M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| JUPW | Safety Shot | $6.20M | $910.01K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| ACRX | Talphera | $651.00K | $117.00K |
AVDL Revenue FAQ
What is Avadel Pharmaceuticals’s yearly revenue?
Avadel Pharmaceuticals's yearly revenue for 2023 was $27.96M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. AVDL's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Avadel Pharmaceuticals’s quarterly revenue?
Avadel Pharmaceuticals's quarterly revenue for Q2 2024 was $41.5M, a 113.36% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $19.45M, a 177.35% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). AVDL's quarterly revenue for Q3 2023 was $7.01M, a 368.85% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Avadel Pharmaceuticals’s revenue growth rate?
Avadel Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -52.78%.
What are Avadel Pharmaceuticals’s revenue streams?
Avadel Pharmaceuticals's revenue streams in c 20 are Vazculep, Other Products, Bloxiverz, and Akovaz. Vazculep generated $10.43M in revenue, accounting 46.70% of the company's total revenue Other Products generated $159K in revenue, accounting 0.71% of the company's total revenue Bloxiverz generated $2.2M in revenue, accounting 9.85% of the company's total revenue Akovaz generated $9.54M in revenue, accounting 42.74% of the company's total revenue
What is Avadel Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of Avadel Pharmaceuticals was Vazculep. This segment made a revenue of $10.43M, representing 46.70% of the company's total revenue.